Compare Harley-Davidson Inc (HOG) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Harley-Davidson Inc trades at $26.92 (market cap $2.86B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Harley-Davidson Inc is far larger — about 2.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Harley-Davidson Inc pays a 2.73% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Harley-Davidson Inc for 92 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HOG | MRVI | |
|---|---|---|
Market Cap | $2.86B | $972.90M |
Volume | 1,391,703 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $28.46 | $9.00 |
52-Week Low | $17.19 | $2.83 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $3.27B | $1.08B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.96, down 1.5% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 EPS beat ($0.75 actual vs. $0.645 expected) but missed in Q4 2025 and Q1 2026. Revenue has declined from $5.8B in 2022 to $4.5B in 2025, with net income margin falling to 4.78%. Recent news highlights tariff risks and a data breach investigation, while analyst consensus is a $28.50 price target with a Hold-heavy rating.
The outlook is cautious; HOG faces revenue pressure and margin compression, offset by low valuation multiples (P/E 15.26, P/S 0.74) and a dividend. Key risks include competitive threats, tariff exposure, and economic sensitivity. Upside depends on execution of the 'Back to the Bricks' plan stabilizing sales, but investor sentiment remains neutral amid institutional selling and mixed earnings trends.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
